Bollard Group LLC bought a new position in shares of Magenta Therapeutics Inc (NASDAQ:MGTA) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 30,000 shares of the company’s stock, valued at approximately $360,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of MGTA. Point72 Asset Management L.P. acquired a new stake in shares of Magenta Therapeutics during the second quarter worth $109,000. Point72 Hong Kong Ltd acquired a new stake in shares of Magenta Therapeutics during the second quarter worth $109,000. Tiverton Asset Management LLC acquired a new stake in shares of Magenta Therapeutics during the second quarter worth $125,000. Northern Trust Corp acquired a new stake in shares of Magenta Therapeutics during the second quarter worth $179,000. Finally, Dean Capital Investments Management LLC acquired a new stake in shares of Magenta Therapeutics during the second quarter worth $558,000. 30.31% of the stock is owned by institutional investors.

Shares of NASDAQ MGTA opened at $7.17 on Friday. Magenta Therapeutics Inc has a 52 week low of $6.10 and a 52 week high of $16.33.

Magenta Therapeutics (NASDAQ:MGTA) last issued its quarterly earnings results on Thursday, November 8th. The company reported ($0.49) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.67) by $0.18. Research analysts predict that Magenta Therapeutics Inc will post -3.19 EPS for the current year.

Separately, Zacks Investment Research upgraded Magenta Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 10th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Magenta Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $19.33.

TRADEMARK VIOLATION NOTICE: This piece was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2018/11/16/30000-shares-in-magenta-therapeutics-inc-mgta-purchased-by-bollard-group-llc.html.

Magenta Therapeutics Company Profile

Magenta Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases.

Featured Article: Bond

Want to see what other hedge funds are holding MGTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Magenta Therapeutics Inc (NASDAQ:MGTA).

Institutional Ownership by Quarter for Magenta Therapeutics (NASDAQ:MGTA)

Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.